

Editor in Chief
Maurizio Rossini

Scientific Committee

Francesco Bertoldo
Andrea Fagiolini
Andrea Giusti
Davide Gatti
Sandro Giannini
Paolo Gisondi
Giovanni Iolascon
Stefano Lello
Diego Peroni
Gianenrico Senna
Pasquale Strazzullo
Giovanni Targher
Leonardo Triggiani

Editorial Assistant
Sara Rossini

Copyright by
Pacini Editore srl

Managing Editor:
Patrizia Pacini

Publisher
Pacini Editore Srl
Via Gherardesca 1 • 56121 Pisa
Tel. 050 313011 • Fax 050 3130300
Info@pacinieditore.it
www.pacinieditore.it

B.U. Pacini Editore Medicina
Andrea Tognelli
Medical Project - Marketing Director
Tel. 050 3130255
atognelli@pacinieditore.it

Copy Editor
Lucia Castelli
Tel. 050 3130224
lcastelli@pacinieditore.it

Graphics and Layout
Massimo Arcidiacono
Tel. 050 3130231
marcidiacono@pacinieditore.it

Print
Industrie Grafiche Pacini • Pisa

Vitamin D - Updates is registered at the Court of Pisa,
n. 2/18 - February 23, 2018

The Publisher remains at the complete disposal of those with rights whom it was impossible to contact, and for any omissions. Photocopies, for personal use (for reading, consultation and study purposes), are permitted within the limits of 15% of each volume or journal issue, excluding advertising, by payment to SIAE of the charge due, in compliance with current regulations on copyright (Law 633, 1941), and specific authorization in writing from CLEARedi: <https://www.clearedi.org/topmenu/HOME.aspx>. Digital Edition July 2020.

Maurizio Rossini

Department of Medicine,
Section of Rheumatology, University of Verona

Dear Readers,

I hope this new issue finds you all well.

Once again, we present important contributions on two topics of great relevance in the field of possible extra skeletal effects of vitamin D: an update on the relationship between vitamin D and muscle and another on its connection with asthma and with respiratory infections, which represent one of the major causes of the exacerbation of asthma; indeed, the latter topic could not but elicit references to the theme on everyone's mind today – the COVID-19 infection.

As you can see from the bibliographical selection of this issue, we deemed it correct to devote some space to the many publications on vitamin D and COVID-19. The debate currently in progress concerns two aspects in particular: is it possible that vitamin D status conditions the risk of COVID-19 infection and/or its clinical manifestations?

As you well know, the rational premises for such a connection are in place. Indeed, the state of our current knowledge allows us to summarize the following points, the first of which are general and the latter more specific:

- general:
 - *in vitro* studies have shown that vitamin D improves the innate immune response, such as the macrophage response, and can increase antiviral defense by stimulating the production of antimicrobial peptides such as cathelicidin and β -defensin;
 - observational studies have provided evidence of an association between low serum levels of 25(OH)D and susceptibility to respiratory infections;
 - a recent meta-analysis has shown that daily or weekly vitamin D supplementation significantly reduces the risk of contracting acute infections of the respiratory tracts, and in particular in subjects with vitamin D deficiency (which is not at all surprising);
 - researchers and institutes, including the AIFA, recognize that vitamin D has an “immunomodulatory” effect; in particular, vitamin D has been shown to be able to attenuate adaptive immune response, especially from cytokines (above all IL-6), by reducing the reaction of the acute post-viral phase, which when pronounced contributes to the pathogenesis of the most serious clinical manifestations of the viral infection (so-called “friendly fire” damage);
 - vitamin D supplementation in patients undergoing mechanical ventilation for various causes has been proven to be able to reduce the duration of hospitalization as well as PCR and IL6 levels;
- specific for COVID-19:
 - higher mortality in the countries of southern Europe (Italy and Spain), which are known for a greater prevalence of vitamin D deficiency, compared to those of northern Europe (Germany, Norway, Finland and Iceland) whose dietary intake of vitamin D is greater, thanks in part to the regular practice of fortifying foods;
 - greater prevalence of COVID-19 infections in the regions of northern Italy, with respect to the sunnier ones of the south or to the greater exposure to the sun of populations below the 35th parallel;
 - a particular incidence and seriousness of the infection in the elderly, in whom hypovita-

Correspondence

Maurizio Rossini
maurizio.rossini@univr.it

How to cite this article: Rossini M. Editoriale. Vitamin D - UpDates 2020;3(3):76-77.

© Copyright by Pacini Editore srl



This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

minosis D is notoriously and historically endemic, especially in the months of winter and early spring; hypovitaminosis D is dramatically and chronically present during long-term hospitalization;

- obesity, which is often associated with hypovitaminosis D, has been shown to be a significant risk factor for COVID-19 morbidity and mortality;
- an inverse correlation between serum vitamin levels and incidence of and mortality from COVID-19;
- an inverse relationship between 25(OH) D levels and the severity of systemic inflammation and clinical manifestations in patients hospitalized for COVID-19, even if we must admit here that it is known that phlogosis by itself reduces measurable 25(OH)D levels;
- modulation on the part of vitamin D of the renin-angiotensin system and the expression of the ACE2 receptor, recog-

nized as the entry point of the virus into human cells.

As you see, there is biological plausibility for a protective role of vitamin D with regard to the risk and/or seriousness of the clinical manifestations of COVID-19 infections.

Plausibility, however, is not enough.

Hasty and general proclamations about a protective role of vitamin D which are not supported by appropriate and specific scientific evidence have already led Italy's Ministry of Health to characterize this supposed connection as a hoax. And yet I would not immediately rule out the possibility of benefits because, conversely, we have no scientific evidence proving that vitamin D does not have an effect. While we await the results of the specific trials that are currently underway, to actually discourage safe and cost-effective vitamin D supplementation, especially in the elderly or in those forced to remain

at home or in hospital, does not seem to me to be opportune during COVID-19 emergency conditions, in particular if we at least consider its recognized skeletal benefits.

Among other things, I worry about the reduction of over 30% of vitamin D supplementation observed in the first months of the year, including in the elderly, in the wake of AIFA's publication of "note 96", which ignores advanced age as a risk factor for hypovitaminosis D, not taking into consideration the progressive reduction of the skin's ability to synthesize vitamin D from the age of 60 (my age!) and the seasonal nadir. Perhaps it is just an unfortunate coincidence that these two factors played a role in the peak of the COVID-19 infection in Italy. In any case, the question presents us with another reason for worrying about the skeletal health of the elderly.

What do you think?

I hope you enjoy reading this issue.